Data Quality in Atopic Dermatitis Clinical Trials

This technical report discusses the significance of accurate measurement in clinical trials for Atopic Dermatitis (AD), focusing on the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA) as primary tools. It outlines the necessity of evaluating AD severity to assess treatment efficacy, referencing the Harmonizing Outcome Measures for Eczema (HOME) group's defined outcomes. The report details the methodologies of EASI and BSA, explaining their differences in measuring disease severity. It presents findings from a study by Signant Health, which highlighted discrepancies between BSA_R9 and EASI_BSA scores in a sample of patients. The report emphasizes the importance of standardization and rater training to improve data quality in dermatology trials. It concludes that understanding measurement tools and implementing strategies can enhance the reliability of clinical trial outcomes, ultimately contributing to the success of treatments for AD.